COMPASS THERAPEUTICS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
COMPASS THERAPEUTICS, INC. (CMPX) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 25.30 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-06
- COMPASS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 25.30M shares, a 17.67% increase year-over-year.
- COMPASS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 24.90M shares, a 15.81% increase year-over-year.
- COMPASS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-09-30 was 18.40M shares, a 6.36% increase year-over-year.
- COMPASS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 21.50M shares.
- COMPASS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 17.38M shares, a 2.51% decline from fiscal 2024.
- COMPASS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 17.83M shares, a 90.15% increase from fiscal 2023.
- COMPASS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 9.38M shares, a 44.89% increase from fiscal 2022.
- COMPASS THERAPEUTICS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 6.47M shares, a 21.41% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 25.30M shares 10-Q · filed 2026-08-06 | 25.30M shares 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 24.90M shares 10-Q · filed 2026-05-05 | |||
| 2025-12-31 | 17.38M shares 10-K · filed 2026-03-05 | |||
| 2025-09-30 | 18.40M shares 10-Q · filed 2025-11-05 | 18.40M shares 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 21.50M shares 10-Q · filed 2026-08-06 | 21.50M shares 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | 21.50M shares 10-Q · filed 2026-05-05 | |||
| 2024-12-31 | 17.83M shares 10-K · filed 2026-03-05 | |||
| 2024-09-30 | 17.30M shares 10-Q · filed 2025-11-05 | 17.30M shares 10-Q · filed 2025-11-05 | ||
| 2023-12-31 | 9.38M shares 10-K · filed 2025-02-27 | |||
| 2022-12-31 | 6.47M shares 10-K · filed 2024-03-21 | |||
| 2021-12-31 | 5.33M shares 10-K · filed 2023-03-15 | |||
| 2020-12-31 | 3.06M shares 10-K · filed 2022-03-18 | |||
| 2020-09-30 | 2.72M shares 10-Q · filed 2020-11-09 | |||
| 2020-06-30 | 1.25M shares 10-Q · filed 2020-08-13 | |||
| 2019-12-31 | 35.66M shares 10-K · filed 2021-03-05 | |||
| 2019-09-30 | 35.66M shares 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | 35.78M shares 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |